OSI Systems, Inc. — Form 10-Q Summary
Business context and reporting period
OSI Systems designs and manufactures specialized electronic systems and components and provides security screening services across Security, Healthcare, and Optoelectronics and Manufacturing divisions. The filing covers the three months ended September 30, 2012, the first quarter of fiscal 2013, compared with the three months ended September 30, 2011. Financial statements are unaudited.
Key financial metrics
| Metric | Q1 FY2013 | Q1 FY2012 | Change |
|---|---|---|---|
| Net revenues | $181.7 million | $161.3 million | Up 13% |
| Gross profit | $61.4 million | $52.9 million | Up 16% |
| Gross margin | 33.8% | 32.8% | Up 1.0 percentage point |
| Income from operations | $10.1 million | $7.6 million | Up 33% |
| Operating margin | 5.6% | 4.7% | Improved |
| Net income | $6.3 million | $4.8 million | Up 33% |
| Diluted EPS | $0.31 | $0.24 | Up $0.07 |
| Cash flow from operations | $42.4 million | $10.0 million | Up $32.4 million |
| Capital expenditures | $62.7 million | $3.1 million | Up $59.6 million |
Security revenue increased 14% to $82.9 million, Healthcare revenue increased 11% to $51.6 million, and Optoelectronics and Manufacturing revenue, including intersegment revenue, increased 8% to $57.1 million. Product revenue was $148.9 million and service revenue was $32.8 million.
SG&A increased 16% to $39.9 million, reflecting costs supporting sales growth and the Mexico program. R&D increased 4% to $11.3 million. Interest and other expense increased to $1.1 million from $0.8 million. The effective tax rate was 29.7%, compared with 30.1%.
At September 30, 2012, cash and cash equivalents were $73.7 million, down from $91.5 million at June 30, 2012. Working capital was $273.1 million, down from $322.5 million. Total debt was approximately $13.8 million, including a newly entered $11.1 million term loan. No borrowings were outstanding under the $425 million revolving credit facility, although letters of credit totaled $193.0 million. The company also had $10.7 million outstanding under foreign letter-of-credit facilities and $34.1 million of availability under those facilities.
Material changes versus the prior comparable period
- Revenue growth was led by higher conventional security equipment sales, radiation and nuclear sensing products, patient monitoring products, and contract manufacturing sales.
- Gross margin improved primarily because of favorable Security sales mix and stronger Healthcare sales, partly offset by an unfavorable Optoelectronics and Manufacturing mix.
- Operating cash flow rose substantially because of favorable working-capital movements, particularly accounts payable, inventory, and accounts receivable.
- Investing cash use increased sharply because of $62.7 million of capital expenditures for the Mexico program and a new Healthcare headquarters and manufacturing facility.
- The company borrowed $11.1 million to acquire Washington State property and repurchased or withheld shares costing $9.4 million. It also received $3.0 million from stock option exercises and its employee stock purchase plan.
- Stock-based compensation expense increased to approximately $3.5 million from $1.5 million, primarily within SG&A.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide specific quantitative revenue or earnings guidance. Management stated that it had begun recognizing revenue under a six-year Mexican government turnkey security-screening agreement covering borders, ports, and airports. The company received a $100 million customer advance associated with the project and is required to provide a guarantee until the advance is earned.
Management noted that Healthcare customers had delayed purchases during the worldwide economic slowdown, although recent product launches and improving North American conditions supported current-quarter growth. A prolonged delay in healthcare purchasing could materially affect results.
- Contingent consideration from acquisitions has a maximum potential amount of $63 million; $20.8 million was recorded in other long-term liabilities at September 30, 2012.
- The company is subject to ordinary-course legal claims and an environmental matter involving soil and groundwater contamination at its Hawthorne, California facility. No loss accrual was recorded because unfavorable outcomes were not considered probable and reasonably estimable; an adverse resolution could be material.
- International operations expose the company to currency, geopolitical, regulatory, collection, and tariff risks. A 10% change in the U.S. dollar relative to local currencies was estimated to affect quarterly operating income by approximately $2 million in the opposite direction.
- The company had approximately $6.2 million of foreign-currency forward contracts and an interest-rate swap related to the new term loan. The swap effectively fixed the loan rate at 2.2% through maturity.
- Management reported effective disclosure controls as of September 30, 2012 and no material changes in internal control over financial reporting. No material changes were reported to the risk factors in the prior Form 10-K.
Investor verification points
- Verify the timing, profitability, cash conversion, guarantees, and remaining obligations associated with the Mexican turnkey screening program.
- Assess whether the unusually high capital expenditures will generate expected returns and whether additional project funding will be required.
- Monitor cash balances, letters of credit, customer advances, debt covenant compliance, and availability under the revolving credit facility.
- Evaluate the sustainability of margin improvement given higher SG&A, increased stock-based compensation, and division-level sales mix.
- Review contingent acquisition payments, legal proceedings, and the Hawthorne environmental exposure for potential cash or earnings impact.
- Confirm the recovery and demand outlook for Healthcare products and the effect of international currency and geopolitical conditions.